Impact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthma
Authors:
Open Access
- 6 August 2025
- journal article
- Published by Taylor & Francis in Journal of Asthma
- p. 1-12
Abstract
Age of asthma onset is critical for determining heterogeneous asthma phenotypes. How onset and duration affect therapeutic response is not well understood. Phase 3 QUEST (NCT02414854) and open-label extension TRAVERSE (NCT02134028) studies demonstrated dupilumab's efficacy up to three years in patients ≥12 years with uncontrolled, moderate-to-severe asthma. We assessed how age of asthma onset and asthma duration affect clinical efficacy of dupilumab in patients with moderate-to-severe type 2 inflammatory asthma. This post hoc analysis included patients with type 2 asthma from QUEST who enrolled in TRAVERSE. Annualized severe exacerbation rates (AER), change from parent study baseline (PSBL) in pre-bronchodilator forced expiratory volume in 1 s (FEV1), and five-item Asthma Control Questionnaire (ACQ-5) score were assessed according to asthma age of onset (40 years) and duration (1 (TRAVERSE Week 96 change from PSBL range, 0.20-0.44 L), and reduced ACQ-5 scores (TRAVERSE Week 48 change from PSBL range, -1.63 to -1.84). In patients who received placebo during QUEST, treatment with dupilumab in TRAVERSE improved AER, FEV1, and ACQ-5 in all subgroups. In patients with uncontrolled, moderate-to-severe type 2 asthma, treatment with dupilumab provides sustained, long-term exacerbation rate reductions and improvements in lung function and asthma control, across all subgroups, with higher reductions in AER and improvements in pre-bronchodilator FEV1 seen in patients with later onset or longer duration.Keywords
Funding Information
- Sanofi and Regeneron Pharmaceuticals Inc (NCT02414854, NCT02134028)
This publication has 40 references indexed in Scilit:
- Effects of dupilumab on mannitol airway hyperresponsiveness in uncontrolled severe asthmaJournal of Allergy and Clinical Immunology, 2024
- Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- Real-life effects of dupilumab on airway oscillometry in severe uncontrolled asthmaAnnals of Allergy, Asthma & Immunology, 2023
- Biologics in the treatment of asthma in children and adolescentsJournal of Allergy and Clinical Immunology, 2023
- Characterization of Asthma by Age of Onset: A Multi-Database Cohort StudyThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Remission and Changes in Severity Over 30 Years in an Adult Asthma CohortThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe AsthmaAdvances in Therapy, 2018
- Severe Asthma in ChildrenThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Asthma outcomes: Pulmonary physiologyJournal of Allergy and Clinical Immunology, 2012